Loading…
Bicara Therapeutics Inc. is projected to rise to $38.45 by 2027, a +33% move from its current price of $28.91. BCAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $28.15 | $28.92 | $29.71 | +0.03% |
| Jul 14 | $27.84 | $28.93 | $30.05 | +0.05% |
| Jul 15 | $27.61 | $28.93 | $30.32 | +0.08% |
| Jul 16 | $27.42 | $28.94 | $30.55 | +0.10% |
| Jul 17 | $27.25 | $28.95 | $30.75 | +0.13% |
| Jul 18 | $27.10 | $28.96 | $30.93 | +0.16% |
| Jul 19 | $26.97 | $28.96 | $31.11 | +0.18% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.97 | $28.96 | $31.11 | +0.18% |
| Week 2 | $26.23 | $29.02 | $32.10 | +0.37% |
| Week 3 | $25.69 | $29.07 | $32.90 | +0.55% |
| Week 4 | $25.24 | $29.12 | $33.59 | +0.73% |
| Week 5 | $24.87 | $29.17 | $34.23 | +0.92% |
| Week 6 | $24.54 | $29.23 | $34.82 | +1.10% |
| Week 7 | $24.24 | $29.28 | $35.37 | +1.28% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
The company was incorporated in 2018 and is based in Boston, Massachusetts.
Bicara operates in the Healthcare category, pursuing therapies aimed at solid tumor cancers.
Bicara Therapeutics Inc. (BCAX) currently trades at $29.34. This positions the company as a healthcare company with a current share price in the high teens to low thirties range depending on market activity.
Its market capitalization is $1.93B and it is ranked 1978. These metrics place Bicara among mid-cap clinical-stage biopharma peers, with a price evolving in a volatile sector driven by clinical outcomes and regulatory milestones.
The price outlook, based on the provided forecast, shows upside potential over the coming years. The forecast projects an average price of $29.34 in 2026 and rising toward higher levels in later years, including $77.66 as the 2030 average, with continued bullish sentiment into 2040 and 2050.
A major floor 46.2% below — a decisive break under it would weaken the trend.
The nearest floor, 32.1% below — buyers have tended to step in here.
The nearest ceiling, 5.2% above — a clean break opens room to run.
A major ceiling 28.2% above — clearing it would confirm fresh momentum.
Key BCAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BCAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.44 | Sell | $29.20 | Sell |
| MA 10 | $29.10 | Sell | $28.52 | Buy |
| MA 20 | $26.26 | Buy | $26.83 | Buy |
| MA 50 | $23.26 | Buy | $24.18 | Buy |
| MA 100 | $21.47 | Buy | $22.05 | Buy |
| MA 200 | $19.03 | Buy | $19.75 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 66.01 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | 62.01 | Neutral |
| Williams %R (14) | -25.47 | Info |
| MACD (12,26,9) | 0.19 | Buy |
| ROC (12) | 15.64 | Buy |
| Bollinger %B (20,2) | 0.71 | Neutral |
| Stochastic %K (14) | 74.53 | Neutral |
| TRIX (15) | 1.21 | Buy |
| Awesome (5,34) | 5.43 | Buy |
| Ultimate (7,14,28) | 55.34 | Neutral |
| Momentum (10) | 2.57 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 29.51 | Sell |
| ADX (14) | 37.78 | Buy |
| ATR (14) | 0.71 | Info |
The 30-day technical picture is bullish with RSI(14) at 80. This suggests strong near-term upside momentum and potential overbought conditions, warranting cautious monitoring.
Key moving averages are $22.25 for the SMA50 and $18.30 for the SMA200, indicating the stock has recently moved above its shorter-term average while remaining above the longer-term trend. Support is at $19.29 and resistance at $29.34, framing a clear trading range as momentum persists.
The 30-day price range spans from $24.23 to $35.53, illustrating a notable up-and-down within the near term. Investors should watch how price action interacts with the current resistance around $29.34 and whether the stock sustains gains above that level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $14.06 | $28.91 | $39.52 | 0% | Neutral | |
| $30.65 | $38.45 | $51.03 | +33% | Bullish | |
| $43.76 | $56.44 | $77.69 | +95% | Bullish | |
| $50.54 | $66.70 | $94.48 | +131% | Bullish | |
| $56.68 | $76.32 | $110.74 | +164% | Bullish | |
| $66.73 | $91.51 | $135.61 | +217% | Bullish | |
| $68.80 | $95.98 | $144.94 | +232% | Bullish | |
| $77.15 | $109.37 | $168.01 | +278% | Bullish | |
| $93.90 | $135.15 | $210.91 | +368% | Bullish | |
| $111.12 | $162.28 | $256.97 | +461% | Bullish | |
| $164.29 | $256.31 | $431.51 | +787% | Bullish | |
| $335.61 | $586.54 | $1,079.66 | +19.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $14.06 | $28.91 | $35.52 | +0.00% |
| August 2026 | $25.50 | $30.08 | $36.44 | +4.05% |
| September 2026 | $24.92 | $29.60 | $36.26 | -1.59% |
| October 2026 | $25.42 | $30.39 | $37.56 | +2.64% |
| November 2026 | $26.23 | $31.51 | $39.26 | +3.71% |
| December 2026 | $26.10 | $31.50 | $39.52 | -0.05% |
Click any year to see its month-by-month BCAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The BCAX price prediction for 2026 points to an average of $28.91 (low $14.06, high $39.52) — a potential gain of 0% on today's $28.91. A consolidation phase looks the most probable path here.
In 2027, BCAX is projected to trade between $30.65 and $51.03, averaging $38.45 — a potential gain of +33% from today's $28.91. That is up +33% on the projected 2026 average. Momentum favours further upside here.
Bicara Therapeutics Inc.'s 2028 outlook centres on $56.44, within a $43.76 to $77.69 range. That is up +47% on the projected 2027 average. That marks a +95% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, BCAX could reach as high as $94.48, with a base case around $66.70 and support toward $50.54 — roughly +131% from $28.91. Momentum favours further upside here.
Expect BCAX to range from $56.68 to $110.74 through 2030. The $76.32 average target implies a +164% move from current prices. That is up +14% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The BCAX price prediction for 2031 points to an average of $91.51 (low $66.73, high $135.61) — a potential gain of +217% on today's $28.91. Momentum favours further upside here.
In 2032, BCAX is projected to trade between $68.80 and $144.94, averaging $95.98 — a potential gain of +232% from today's $28.91. That is up +5% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Bicara Therapeutics Inc.'s 2033 outlook centres on $109.37, within a $77.15 to $168.01 range. That is up +14% on the projected 2032 average. That marks a +278% change versus current levels. Momentum favours further upside here.
By 2034, BCAX could reach as high as $210.91, with a base case around $135.15 and support toward $93.90 — roughly +368% from $28.91. Buyers look set to stay in control over this stretch.
Expect BCAX to range from $111.12 to $256.97 through 2035. The $162.28 average target implies a +461% move from current prices. That is up +20% on the projected 2034 average. Momentum favours further upside here.
The BCAX price prediction for 2040 points to an average of $256.31 (low $164.29, high $431.51) — a potential gain of +787% on today's $28.91. Buyers look set to stay in control over this stretch.
In 2050, BCAX is projected to trade between $335.61 and $1,079.66, averaging $586.54 — a potential gain of +19.3x from today's $28.91. That is up +129% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in BCAX today (≈ 34.590107 BCAX) could be worth
$20,288.63
+$19,288.63 (+1929%) by 2050 · US Dollar
Based on the average projected BCAX price of $586.54 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BCAXwould be worth at today's price.
$1,000 invested in BCAX on Jul 10, 2025 (≈ 100.806451 BCAX) would be worth
$2,914.31
+$1,914.31 (+191.4%) today · 2.91× · US Dollar
Based on a BCAX entry price of $9.92 vs. today's $28.91.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29 | $996.9 | -0.3% |
| 1 month ago | $20.21 | $1,430.48 | +43.0% |
| 3 months ago | $21.12 | $1,368.84 | +36.9% |
| 6 months ago | $17.43 | $1,658.63 | +65.9% |
| 1 year ago | $9.92 | $2,914.31 | +191.4% |
| All time (1.8y) ago | $23.41 | $1,234.94 | +23.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BCAX forecast.
Our base-case forecast reaches $58.00 around 2029.
Implied market cap at $58.00: $3.81B
The multi-year forecast shows a progressively higher price trajectory with bullish sentiment entering the later years. In 2026, the min is $14.06, the avg is $29.34, and the max is $40.34, with a neutral sentiment.
In 2027, the min is $31.87, the avg is $40.31, and the max is $54.08, with a bullish sentiment and an ROI of 37.4%. In 2028, the min is $45.26, the avg is $58.96, and the max is $82.21, with an ROI of 101 and a bullish stance.
By 2030, the min is $56.89, the avg is $77.66, and the max is $114.46, with an ROI of 164.7 and a bullish sentiment. The forecast continues higher in 2031–2035, and into 2040 and 2050, with 2040 at an avg of $258.11 (min $160.94, max $444.82, ROI 779.7) and 2050 at an avg of $570.04 (min $313.33, max $1,078.63, ROI 1842.9), both with bullish sentiment. These are estimates, not guarantees, and reflect potential upside under favorable conditions while recognizing inherent investment risk.
Tap a question to reveal the answer.
The forecasted average price in 2030 is $77.66, with a min of $56.89 and a max of $114.46, and ROI of 164.7%; sentiment BULLISH.
Forecasts show bullish sentiment in 2027 through 2050, with rising averages: 2027 avg $40.31, 2028 avg $58.96, 2029 avg $67.45, 2030 avg $77.66, and 2050 avg $570.04. These are estimates, not guarantees.
Yes. The 2030 max is $114.46, and the 2031 max is $139.28, with higher-year maxes (2032 $145.21; 2033 $172.93), indicating the potential to exceed $100.
Current price is $29.34; market cap is $1.93B.
For 2040, avg $258.11 with min $160.94, max $444.82 and sentiment BULLISH; for 2050, avg $570.04 with min $313.33, max $1,078.63 and sentiment BULLISH.
Bicara Therapeutics Inc. Community Discussion
0Share your Bicara Therapeutics Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.